ZURA · Zura Bio Ltd · Metrics
$4.13
+0.13 (+3.25%)
At close · Oct 21
Return incl. dividend (before tax)
Market Cap
$391.95M
Shares
95.83M
Volume · Oct 21
4.17M
Avg daily vol (3M)
2.11M
ZURA metrics
61 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$4.00
Market cap
$391.95M
Price action
20 metricsPrice change (1W)
-5.4%
Price change (30D)
-11.1%
Price change (3M)
-29.6%
Price change (6M)
-24.4%
Price change (YTD)
-23.7%
Price change (1Y)
+18.7%
Trailing year
Price change (5Y)
—
52-week high
$7.04
52-week low
$3.33
Change from 52-week high
-43.2%
Change from 52-week low
+20.1%
Annualized volatility
78.2%
Annualized volatility (3M)
58.8%
Beta
1.6
RSI (14D)
40.9
Price vs SMA 50
-19.2%
Price vs SMA 200
-24.3%
Avg volume (3M)
2.11M
Relative volume
1.6
Average dollar volume
$10.02M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
95.83M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
2.0
reciprocal yield 49.8%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-21.7%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$92.75M
Net income (TTM)
−$85.74M
Trailing 12 months
Diluted EPS (TTM)
$-1.13
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+34.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-43.5%
Return on assets
-40.2%
Debt / equity
0.0
Current ratio
12.9
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
12.9
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$205.13M
Latest balance sheet
Cash & equivalents
$205.13M
Total assets
$213.40M
Total debt
$0
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$64.83M
Capital expenditures (TTM)
$112,973
R&D (TTM)
$58.36M
SG&A (TTM)
—
Stock compensation (TTM)
$12.33M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
97
13F filer change QoQ
+3
Institutional ownership
76.3%
Conviction holders (share of 13F filers)
1.1%
Crowding (high-turnover and private-fund holders)
49.9%
Private-fund adviser ownership
49.6%
Active holders' share change QoQ
+1.0%
Holder tenure
7.5
Price vs estimated holder cost
+27.0%
Ownership (registered funds)
1 metricsIndex-fund ownership
0.9%
Short interest
3 metricsShort interest
9.8%
Latest settlement · 4.8 days to cover
Days to cover
4.8d
Short-squeeze score
69 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—